AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01256853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA Vaccine
Description: The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.
Study NCT03418116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argus II Retinal Prosthesis
Description: The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
Study NCT02780232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cuida tu animo / Care for your mood
Description: CUIDA TU ÁNIMO is an online program to adolescents that provides information, education and support related to the care of the mood.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links. The website have the following modules:~1. What is 'CUIDA TU ÁNIMO': Description and definition of the program~2. Psycho-educational information: Information about depression, its treatment, and opportunities for prevention~3. How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback~4. Forums.~5. Blog.~6. Appointment (Chat or Phone call).~7. Contact.
Study NCT01222169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
Study NCT01222169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0,9%
Description: Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
Study NCT00440869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg po bid
Study NCT00440869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: bid oral dosing
Study NCT04646239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heterologous stimuli
Description: In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli
Study NCT04646239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutralization assay
Description: In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2
Study NCT04035213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior of Sleep Course
Description: The current study will evaluate whether a semester-long course focused on sleep improves college students' sleep patterns over one semester compared to students completing a similar-level course in the same department (Psychology) at the same university.
Study NCT03724487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coachman
Description: Coachman is comprised of: TBI and nurse counseling. TBI is comprised of: 1) web-based education modules on hypertension knowledge and skills as well as behavioral lifestyle guidance, (2) Medisafe, a smartphone medication management app to support medication adherence to antihypertensives, and (3) self-monitoring blood pressure. Participants will be exposed to nurse counseling, by registered nurses from the community, affiliated with a local nurse organization that will serve as community health workers (CHWs). The CHWs will provide informal counseling, social support, as well as follow-up phone sessions on medication adherence and monitoring blood pressure.
Study NCT03724487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EUC)
Description: Standard printed education materials on hypertension management, including content on lifestyle modification and medication-taking will be provided; plus access to one web-based education (video) with information on how to self-monitoring blood pressure.
Study NCT01945151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).
Description: The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
Study NCT01559233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FPlus RF device for wrinkles and rhytide reduction
Description: Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
Study NCT01519492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFN-12520000
Description: Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
Study NCT01373931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study NCT01373931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho Cyclen
Description: 35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally
Study NCT01373931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01720290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: Dose individually adjusted
Study NCT01720290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Dose individually adjusted
Study NCT01720290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Dose individually adjusted
Study NCT01720290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Dose at 1000 mg/day
Study NCT01230255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous catheter drainage
Description: Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
Study NCT01230255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous catheter drainage
Description: Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
Study NCT02333214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergames and conventional physiotherapy
Description: The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
Study NCT02333214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
Study NCT04467385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR training + Sensory Integration therapy + conventional therapy
Description: After the baseline assessment,~* Coconut ShootersVR - 5 min/day~* Ninja flipVR - 5 min/day.~* Sensory integration training include Exercises on BOSU ball and mini-trampoline. It will involve:~* Passive bouncing with child standing with his/her feet shoulder width apart for 2.5 and 2.5 minutes on both.~* Active bouncing (the child bounces and therapist will control the rate) for 2.5 and 2.5 minutes on both.~* Mini-squat exercises with feet apart and feet together for 2.5 and 2.5 minutes on both.~* Conventional exercises include:~  * passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed.
Study NCT04467385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR training + conventional therapy
Description: After the baseline assessment,~* The Your Shape: Fitness Evolved 2012TM game is selected for VR training (walking and walking with obstacles) for 8 min~* Coconut ShootersVR - 8 min/day~* Ninja flipVR - 8 min/day~* Conventional Therapy - 20 min per day~  * Passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest 3-5 times for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed.
Study NCT03001297 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
Study NCT03001297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5884 Dose 1
Description: Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
Study NCT03001297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5884 Dose 2
Description: Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
Study NCT03001297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5884 Dose 3
Description: Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
Study NCT03001297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5884 Dose 4
Description: Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
Study NCT02514018 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Live-attenuated varicella-zoster virus vaccine
Description: Commercial vaccine used to prevent shingles
Study NCT04023864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Platycodon Grandiflorus Extract(GCWB107)
Description: Once-daily, once a tablet, after meals, for 12 week
Study NCT04023864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 week
Study NCT04632602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiological effects of awake prone position in COVID 19 patients
Description: Study of physiological effects of awake prone position in COVID 19 patients on lung inhomogeneity assessed by Electrical Impedance Tomography (EIT), gas exchange and dyspnea score (Borg Scale).~Measurements will be performed at baseline (on supine position), then patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours. EIT records will be performed during the last 30 minutes of each period, blood gas and dyspnea score at the end of each period.
Study NCT01815788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a personal sound amplifying device = TeoFirst
Study NCT04669730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Routine care
Study NCT04669730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walk
Description: Walk 30mins
Study NCT04669730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baduanjin
Description: Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
Study NCT04669730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin plus walk
Description: Walk 30mins then Baduanjin 12mins per day, 5 times per week.
Study NCT03346720 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews
Description: These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.
Study NCT03346720 — intervention group
Intervention type: OTHER
Intervention: Focus group discussions (FGDs)
Description: These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
Study NCT00260143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Study NCT00260143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04290351 — intervention group
Intervention type: PROCEDURE
Intervention: band ligation
Description: Rubber band ligation will be applied to patients, and then phlebotonic will be prescribed.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)
Study NCT04290351 — intervention group
Intervention type: DRUG
Intervention: oral 450 mg diosmin+50 mg hesperidin
Description: 450 mg diosmin + 50 mg hesperidin will be prescribed to patients undergoing band ligation.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)
Study NCT00464646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
Study NCT00464646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
Study NCT00464646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
Study NCT00464646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses
Study NCT00464646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses
Study NCT04050241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope intubation
Description: Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
Study NCT04050241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mcintosh intubation
Description: Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
Study NCT00192309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAIV-T
Description: Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
Study NCT00192309 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
Study NCT00192309 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
Study NCT01083654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Counseling
Description: Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
Study NCT01083654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-Tailored Treatment
Description: The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
Study NCT01972438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASEDs
Description: Experimental Intervention
Study NCT01972438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASEDs
Description: Experimental Intervention
Study NCT02608866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SF-SSRS
Description: Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
Study NCT02608866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MF-SSRS
Description: SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
Study NCT04493931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.
Study NCT04493931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: Cimetidine tablets will be available as unit dose strength 400 mg and will be administered orally.
Study NCT04493931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin Capsules will be available as unit dose strength 300 mg and will be administered orally.
Study NCT04493931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.